Clinical Trials Logo

Filter by:
NCT ID: NCT06049667 Recruiting - Clinical trials for Relapsed/Refractory Acute Myeloid Leukemia (AML)

A Phase 1 Clinical Trail of NTQ2494 Tablets in Patients With Advanced Hematological Malignancies

Start date: August 7, 2023
Phase: Phase 1
Study type: Interventional

NTQ2494 tablet, an anti-tumor molecular targeted drug, is an AXL kinase inhibitor. The objectives were to evaluate the safety and tolerability, PK characteristics and preliminary efficacy of NTQ2494 tablets in patients with advanced hematological malignancies.

NCT ID: NCT06049290 Recruiting - Clinical trials for Relapsed/Refractory Multiple Myeloma

A Phase I/II Clinical Trial of LBL-034 in Patients With Relapsed Refractory Multiple Myeloma

Start date: October 20, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This is a single-arm, open-label, multicenter, dose-escalation, and dose-expansion phase I/II clinical study to evaluate the safety, tolerability, pharmacokinetics, immunogenicity, and efficacy of LBL-034 in patients with R/R MM.

NCT ID: NCT06049186 Recruiting - Clinical trials for Polycystic Ovary Syndrome

CRD vs. Met in Patients With Obese PCOS Infertility

Start date: September 15, 2023
Phase: N/A
Study type: Interventional

Polycystic ovary syndrome (PCOS) is a common gynecological endocrine disease and a major cause of anovulatory infertility in reproductive-aged women. From 2010 to 2020, it was found that the prevalence of PCOS in reproductive-aged women in China reached 7.8%, an increase of 65% over 10 years ago. Many of them are overweight or obese. Weight loss including diet modifications can significantly reduce reproductive and metabolic disorders of PCOS and is recommended as a first step in the treatment of overweight or obese women with PCOS. Many weight loss programs have been proposed, including calorie-restriction diet (CRD) intervention. Whether CRD intervention prior to ovulation induction therapy could improve live birth rates in overweight/obese PCOS women has not been illustrated.

NCT ID: NCT06049017 Recruiting - Colitis, Ulcerative Clinical Trials

A Study of JNJ-77242113 in Participants With Moderately to Severely Active Ulcerative Colitis

ANTHEM-UC
Start date: October 9, 2023
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the safety and effectiveness of JNJ-77242113 compared with placebo in participants with moderately to severely active ulcerative colitis.

NCT ID: NCT06048588 Recruiting - Clinical trials for Atherosclerotic Cardiovascular Disease

YN001 in Healthy Subjects and Patients With Coronary Atherosclerosis

Start date: October 8, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This study consists of two parts. The SAD and MAD of part I are a randomized, double-blind, placebo-controlled, single and multiple ascending dose study in healthy adult subjects. The MAD expansion cohort of part I is single arm and multipal ascending dose in heallthy subjects. Part II (phase Ib/IIa) is a multicenter, randomized, controlled, open label, multiple ascending dose study in patients with coronary atherosclerosis.

NCT ID: NCT06048406 Recruiting - Influenza Clinical Trials

Effect of Health Education on Promoting Influenza Vaccination Health Literacy

Start date: September 11, 2023
Phase: N/A
Study type: Interventional

The goal of this cluster randomized controlled trial is to evaluate the effect of health education interventions on influenza vaccination rates and health literacy in primary school students in the city of Dongguan in China. Individuals aged 7 to 12 years who are in grades 4-5 in primary schools in Dongguan will be enrolled. 20 primary schools will be randomly selected, with half designated as intervention group schools and the remaining half as control group schools. The intervention group will receive a monthly health education intervention focused on influenza vaccination for 5 months, while the control group will continue with their routine school health education for 5 months. Researchers will compare the differences in influenza vaccination rates and influenza vaccination health literacy levels between the intervention and control groups after 5 months to see if health education can promote influenza vaccination health literacy among primary school students.

NCT ID: NCT06048393 Recruiting - COVID-19 Clinical Trials

SA55 Novel Coronavirus Broad-spectrum Neutralizing Antibody Nasal Spray in Health People

Start date: May 31, 2023
Phase: Phase 1
Study type: Interventional

To evaluate the safety, tolerance, local drug content and neutralization activity in nasal cavity, systemic exposure level and immunogenicity of novel coronavirus broad-spectrum neutralizing antibody SA55 nasal spray.

NCT ID: NCT06048367 Recruiting - Breast Cancer Clinical Trials

Carbon Nanoparticle-Loaded Iron [CNSI-Fe(II)] in the Treatment of Advanced Solid Tumor

CNSI-Fe(II)
Start date: October 14, 2022
Phase: Phase 1
Study type: Interventional

This Phase I clinical trial aims to evaluate the safety, tolerability, pharmacokinetics (PK) profile and preliminary efficacy of intratumoral injection of Carbon Nanoparticle-Loaded Iron [CNSI-Fe(II)] in patients with advanced solid tumors. The study also aims to observe dose-limiting toxicities (DLT) of CNSI-Fe(II) to determine the maximum tolerated dose (MTD) or the highest injectable dose in humans, providing dosing guidelines for future clinical studies. CNSI-Fe(II) shows promise as an innovative tumor therapeutic agent due to its unique properties of ferroptosis. The study primarily focuses on assessing the potential efficacy of CNSI-Fe(II) in patients with advanced solid tumors, particularly in patients with Kras mutation, e.g., pancreatic cancer patients.

NCT ID: NCT06048289 Recruiting - Cholangiocarcinoma Clinical Trials

Prospective Observational Study to Predict the Response of Biliary Tract Tumors to Immunotherapy

Start date: September 14, 2023
Phase:
Study type: Observational

A prospective, observational study to explore multidimensional biomarkers for predicting the efficacy of immunotherapy In biliary tract tumors

NCT ID: NCT06048107 Recruiting - HLH Clinical Trials

Teniposide Incorporating Bu/Cy Conditioning Regimen for HLH With Central Nervous System Involvemen

Start date: October 22, 2023
Phase: N/A
Study type: Interventional

Hemophagocytic lymphohistiocytosis (HLH) is a highly inflammatory disease involving cytokine storms and is characterised by rapid progression and high mortality. There are no uniform clinical criteria for the diagnosis of CNS-HLH.And there is still a lack of international consensus on the treatment for CNS-HLH. Following allogeneic HSCT after HLH induction therapy is recommended for CNS-HLH. One of the major factors influencing the transplantation effect is conditioning. Therefore, we conduct a prospective clinical study to explore the efficacy and safety of Teniposide incorporating Bu/Cy conditioning regimen followed by allogeneic hematopoietic stem cell transplantation for HLH with central nervous system involvement.